Clinical Trials

A Phase I Study of BMS-663513 (Anti-CD137 Antibody) in Patients with Advanced or Metastatic Solid Tumors

Protocol
11-212
Full Title
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects with Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
Purpose

BMS-663513 is an investigational drug that works by stimulating the immune system against cancer. It is a monoclonal antibody that stimulates the activity of certain white blood cells by binding to a protein called CD137.

In this study, researchers want to find the optimal dose of BMS-663513 that can be given in patients with advanced or metastatic solid tumors that persist despite standard therapy or for which no standard therapy exists.

Investigator
Neil H. Segal, MD, PhD
Neil H. Segal - Physician Profile
Co-Investigators
Pictured: Jedd Wolchok
Jedd D. Wolchok - Physician Profile
Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have an advanced or metastatic solid tumor that persists despite standard therapy or for which no standard therapy exists.
  • Patients may not have had more than two prior regimens of chemotherapy for relapsed or refractory disease.
  • At least 4 weeks must have passed since completion of prior therapy and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact the office of Dr. Neil H. Segal at 646-888-4187.

Locations
ClinicalTrials.gov